Segment Information And Geographic Data (Tables)

12 Months Ended

Dec. 31, 2012

Segment Information And Geographic Data [Abstract]

Summary Information By Operating Segment



	For the Year Ended December 31,
				2011
				Restated
	2012			(Note 2)		2010
China:
Net Revenues:
ZADAXIN product sales	$	108,127		$	101,193	$	82,012
Other product sales		11,002			7,121		—
Total net product sales		119,129			108,314		82,012
Promotion services revenue		33,098			20,614		—
Total net revenues		152,227			128,928		82,012
Operating income		4,216	⁽¹⁾		47,154		43,754
Long-lived assets		35,541			79,694		202
Rest of the World (including the US):
Net Revenues:
ZADAXIN product sales	$	4,042		$	3,637	$	3,100
Total net revenues		4,042			3,637		3,100
Operating income (loss) ⁽²⁾		2,194			(18,199)		(21,360)
Long-lived assets		832			1,092		1,277

(1)	The operating income for the China segment for the year ended December 31, 2012, includes the $42.7 million impairment charge on the intangible assets.

Operating income (loss) for the Rest of the World segment includes the change in the fair value of the contingent consideration and all research and development expense for the Company’s SCV-07 trial, which was discontinued in the first quarter of 2012.

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details